NANO-X IMAGING LTD - Ordinary Shares (NNOX)

PETACH TIKVA, Israel, Feb. 25, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will present data supporting the Nanox.ARC performance at the 2025 European Congress of Radiology (ECR), taking place February 26 – March 2 in Vienna, Austria.

PETACH TIKVA, Israel, Feb. 25, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has received CE (Conformité Européenne) mark certification to market the multi-source Nanox.ARC system, including the Nanox.CLOUD, its accompanying cloud-based infrastructure.  Nanox.ARC is a stationary X-ray system, intended to generate tomographic images of human anatomy from a single tomographic sweep performed in recumbent positions of adult patients.

PETACH TIKVA, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Nanox.ARC, a stationary X-ray system intended to produce tomographic images for general use including human musculoskeletal system, pulmonary, intra-abdominal, and paranasal sinus indications, adjunctive to conventional radiography, on adult patients.

Made progress deploying all components of the Nanox solution including Nanox.ARC and Nanox.AI

PETACH TIKVA, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended September 30, 2024, before market open on Thursday, November 21, 2024. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.

Nanox AI’s Solutions selected for Special Mention on annual list recognizing the most impactful new products and ideas

PETACH TIKVA, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that Company management will participate in an investor conference in the month of September 2024:

HealthCCSng V2.0 introduces additional ‘zero calcium’ categorization of coronary artery calcium (CAC) and generates a numerical calcium score with corresponding CAC detection category output

Accelerated the deployment of Nanox ARC in the US market,

PETACH TIKVA, Israel, Aug. 06, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended June 30, 2024, before market open on Tuesday, August 20, 2024. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.

In a study conducted by Brigham & Women’s Hospital, Nanox.AI-Based Analysis helps Reveal Coronary Artery Calcium in over 50% of IMID Patients; Lead author Brittany Weber, MD, PhD, declared as ‘Young Investigator Awards’ Winner

On Friday, Serve Robotics' stock surged 187% on remarkable trading volume after NVIDIA disclosed its stake in the company.

PETACH TIKVA, Israel, June 25, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that data from five studies supporting the AI Cardiac Solution (HealthCCSng) of its subsidiary, Nanox AI, will be presented at the 19th Annual Meeting of the Society of Cardiovascular Computed Tomography (SCCT), being held July 18-21 in Washington, D.C.

Nanox integrates FDA-cleared population health AI solutions into its Second Opinions service

Accelerates Deployment of Nanox.ARC in United States

PETACH TIKVA, Israel, May 20, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended March 31, 2024, before market open on Tuesday, May 28, 2024. Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.

Company earns Gold Seal of Approval® for Ambulatory Health Care Accreditation

PETACH TIKVA, Israel, May 07, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announces that Company management will participate in three investor conferences in the month of May 2024:

Vocodia Holdings (CBOE: VHAI) conversational AI product could be in the crosshairs of large sector players following news that the largest of the Magnificent Seven (MS), Nvidia, took a roughly $3.7 million stake in sector competitor SoundHound AI (Nasdaq: SOUN) in Q4/2023. While the technologies between VHAI and SOUN aren't exactly the same, they are definitely in the same "conversational AI" family, which could bode well for Vocodia, considering its technology can feed a red-hot sector that's about to get scorching. And keep this in mind- Nvidia isn't the only kingmaker in the AI sector; there are plenty of others. Therefore, before focusing on companies like SOUN that have had their run, pay attention to the value proposition Vocodia offers, especially at share prices lower than its February IPO.

PETACH TIKVA, Israel, April 22, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (“SEC”) on April 22, 2024. The annual report on Form 20-F, which contains the Company’s audited consolidated financial statements, can be accessed on the SEC’s website at https://www.sec.gov/ and on the Company’s website at https://www.nanox.vision/ under “Financials” in the Investors section.

AhealthZ to aid Nanox’s pursuit of local authorizations and licenses for Nanox.ARC in South Korea

Nanox Launches Nanox.ARC in United States with Installations Across Five States, Marking a Major Advancement in Medical Imaging

Vocodia Holdings (CBOE: VHAI) stock has been churning around the $1.00 level since its February 22nd IPO and CBOE market listing. But that can be good news for investors just now getting acquainted with this potential rising star in the conversational AI space. The stock hasn't been void of attention. Interested investors have been exchanging over a million shares a day since last week. That might not sound like a lot compared to other companies but know this- VHAI only has about 8.3 million shares outstanding, and of those, only about 2.9 million are in the trading float. Thus, with the daily exchange getting shares into tighter hands, it's fair to suggest that once the post-IPO dust settles, the near-term path of least resistance for VHAI stock is higher. That bullish assessment is more than warranted; it's justified.

PETAH TIKVA, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQNNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter and fiscal year ended December 31, 2023, before market open on Monday, April 1, 2024. Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.

– According to early findings in the ADOPT study, Nanox.AI software improves detection of key risk factor for osteoporosis, outperforming UK National Health Service national average